Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide plus chemotherapy vs chemotherapy in newly diagnosed pediatric T-cell acute lymphoblastic leukemia
ChiCTR2300075225Phase 4Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tucidinostat in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Event-free survival. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
tucidinostat
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2300075225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075225.